Literature DB >> 16353949

Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants.

Lankupalle D Jayanthi1, Sammanda Ramamoorthy.   

Abstract

Synaptic neurotransmission in the central nervous system (CNS) requires the precise control of the duration and the magnitude of neurotransmitter action at specific molecular targets. At the molecular level, neurotransmitter signaling is dynamically regulated by a diverse set of macromolecules including biosynthetic enzymes, secretory proteins, ion channels, pre- and postsynaptic receptors and transporters. Monoamines, 5-hydroxytryptamine or serotonin (5-HT), norepinephrine (NE), and dopamine (DA) play an important modulatory role in the CNS and are involved in numerous physiological functions and pathological conditions. Presynaptic plasma membrane transporters for 5-HT (SERT), NE (NET), and DA (DAT), respectively, control synaptic actions of these monoamines by rapidly clearing the released amine. Monoamine transporters are the sites of action for widely used antidepressants and are high affinity molecular targets for drugs of abuse including cocaine, amphetamine, and 3,4-methylenedioxymetamphetamine (MDMA) "Ecstasy." Monoamine transporters also serve as molecular gateways for neurotoxins. Emerging evidence indicates that regulation of transporter function and surface expression can be rapidly modulated by "intrinsic" transporter activity itself, and antidepressant and psychostimulant drugs that block monoamine transport have a profound effect on transporter regulation. Therefore, disregulations in the functioning of monoamine transporters may underlie many disorders of transmitter imbalance such as depression, attention deficit hyperactivity disorder, and schizophrenia. This review integrates recent progress in understanding the molecular mechanisms of monoamine transporter regulation, in particular, posttranscriptional regulation by phosphorylation and trafficking linked to cellular protein kinases, protein phosphatases, and transporter interacting proteins. The review also discusses the possible role of psychostimulants and antidepressants in influencing monoamine transport regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353949      PMCID: PMC2751275          DOI: 10.1208/aapsj070373

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  118 in total

1.  Role of protein kinase C and second messengers in regulation of the norepinephrine transporter.

Authors:  H Bönisch; R Hammermann; M Brüss
Journal:  Adv Pharmacol       Date:  1998

Review 2.  Molecular and cellular basis of addiction.

Authors:  E J Nestler; G K Aghajanian
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

3.  Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor.

Authors:  B A Rocha; K Scearce-Levie; J J Lucas; N Hiroi; N Castanon; J C Crabbe; E J Nestler; R Hen
Journal:  Nature       Date:  1998-05-14       Impact factor: 49.962

4.  Cocaine up-regulates norepinephrine transporter binding in the rat placenta.

Authors:  L P Shearman; J S Meyer
Journal:  Eur J Pharmacol       Date:  1999-12-10       Impact factor: 4.432

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters.

Authors:  G M Daniels; S G Amara
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

7.  Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice.

Authors:  D Bengel; D L Murphy; A M Andrews; C H Wichems; D Feltner; A Heils; R Mössner; H Westphal; K P Lesch
Journal:  Mol Pharmacol       Date:  1998-04       Impact factor: 4.436

8.  Phosphorylation and regulation of antidepressant-sensitive serotonin transporters.

Authors:  S Ramamoorthy; E Giovanetti; Y Qian; R D Blakely
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

9.  Reduced levels of norepinephrine transporters in the locus coeruleus in major depression.

Authors:  V Klimek; C Stockmeier; J Overholser; H Y Meltzer; S Kalka; G Dilley; G A Ordway
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

10.  Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice.

Authors:  I Sora; C Wichems; N Takahashi; X F Li; Z Zeng; R Revay; K P Lesch; D L Murphy; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more
  29 in total

1.  Activity cliffs and activity cliff generators based on chemotype-related activity landscapes.

Authors:  Jaime Pérez-Villanueva; Oscar Méndez-Lucio; Olivia Soria-Arteche; José L Medina-Franco
Journal:  Mol Divers       Date:  2015-07-07       Impact factor: 2.943

2.  Increase in clusterin-containing follicles in the adenohypophysis of drug abusers.

Authors:  Takaki Ishikawa; Bao-Li Zhu; Satoru Miyaishi; Hideo Ishizu; Hitoshi Maeda
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

Review 3.  Drugs, biogenic amine targets and the developing brain.

Authors:  Aliya L Frederick; Gregg D Stanwood
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

Review 4.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

Review 5.  In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening.

Authors:  Xiao Hua Ma; Zhe Shi; Chunyan Tan; Yuyang Jiang; Mei Lin Go; Boon Chuan Low; Yu Zong Chen
Journal:  Pharm Res       Date:  2010-03-11       Impact factor: 4.200

6.  Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice.

Authors:  I Peraile; E Torres; A Mayado; M Izco; A Lopez-Jimenez; J A Lopez-Moreno; M I Colado; E O'Shea
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

7.  Association between polymorphisms in the vesicle-associated membrane protein-associated protein A (VAPA) gene on chromosome 18p and bipolar disorder.

Authors:  Falk W Lohoff; Andrew E Weller; Paul J Bloch; Aleksandra H Nall; Thomas N Ferraro; Wade H Berrettini
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575

8.  Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity.

Authors:  B Chanrion; C Mannoury la Cour; F Bertaso; M Lerner-Natoli; M Freissmuth; M J Millan; J Bockaert; P Marin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

9.  Upregulated mRNA levels of SERT, NET, MAOB, and BDNF in various brain regions of ovariectomized rats exposed to chronic aversive stimuli.

Authors:  Narattaphol Charoenphandhu; Amporn Nuntapornsak; Kannikar Wongdee; Nateetip Krishnamra; Jantarima Charoenphandhu
Journal:  Mol Cell Biochem       Date:  2012-12-04       Impact factor: 3.396

10.  Insertion of tetracysteine motifs into dopamine transporter extracellular domains.

Authors:  Deanna M Navaroli; Haley E Melikian
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.